Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

Exclusion Criteria

• •1. History of treatment with a tyrosine kinase inhibitor (eg, imatinib) or other moderate-to-significant Cyclophilin A4 inhibitor within 2 weeks of enrollment.
• •2. Renal insufficiency as follows: creatinine \> 2.5 mg/deciliters (dL) or Creatinine Clearance \< 30 ml/min.
• •3. Hepatic insufficiency as follows: serum bilirubin \>3 mg/dL or transaminitis \>3x upper limit of normal (ULN) (unless deemed due to GVHD).
• •4. History of cardiac dysrhythmias or known cardiovascular disease without formal Cardiology clearance.
• •5. History of cerebro-vascular accident or intracranial hemorrhage within 6 months prior to enrollment.
• •6. History of non-intracranial hemorrhage and/or coagulopathy without formal Coagulation clearance.
• •7. Uncontrolled infections not responsive to antibiotics, anti-viral medicines, or anti-fungal medicines; or infection requiring systemic treatment that was completed ≤14 days before enrollment.
• •8. History of other hematologic malignancy.
• •9. History of human immunodeficiency virus (HIV).
• •10. History of active hepatitis B virus (HBV) or hepatitis C virus (HCV) without formal Infectious Disease clearance.
• •11. Patients incapable of complying with routine follow up schedule or unable to be compliant with study therapy.
• •12. Active or within 3 months use of prohibited medications or substances (e.g., illicit drugs).